Evidence map›Paper›PMID 28160058›Full record

ArticleLangenbeck's archives of surgery2017

The utility of the Bethesda category and its association with BRAF mutation in the prediction of papillary thyroid cancer stage.

Augustas Beiša, Mindaugas Kvietkauskas, Virgilijus Beiša, Mindaugas Stoškus, Elvyra Ostanevičiūtė, Eugenijus Jasiūnas, Laimonas Griškevičius, Kęstutis Strupas

Abstract read
PubMed Publisher
In one paragraph

Article in Langenbeck's archives of surgery, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Molecular Variants and Their Risks for Malignancy in Cytologically Indeterminate Thyroid Nodules.Thyroid : official journal of the American Thyroid Association · 2019
    Pooled it
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Augustas BeišaCentre of Abdominal Surgery, Vilnius University, Santariškių 2, 08406, Vilnius, Lithuania. augustas.beisa@santa.lt.
Mindaugas KvietkauskasCentre of Abdominal Surgery, Vilnius University, Santariškių 2, 08406, Vilnius, Lithuania.
Virgilijus BeišaCentre of Abdominal Surgery, Vilnius University, Santariškių 2, 08406, Vilnius, Lithuania.
Mindaugas StoškusCentre of Haematology, Oncology and Transfusion Medicine, Vilnius University, Vilnius, Lithuania.
Elvyra OstanevičiūtėCentre of Laboratory Medicine, Vilnius University, Vilnius, Lithuania.
Eugenijus JasiūnasMykolas Romeris University, Vilnius, Lithuania.
Laimonas GriškevičiusCentre of Haematology, Oncology and Transfusion Medicine, Vilnius University, Vilnius, Lithuania.
Kęstutis StrupasCentre of Abdominal Surgery, Vilnius University, Santariškių 2, 08406, Vilnius, Lithuania.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThis study aims to determine the utility of the Bethesda category and its association with BRAF mutation in prediction of the papillary thyroid cancer (PTC) stage.

methodsA prospective study analyzed patients who had ultrasound-suspicious thyroid nodules, underwent FNA and cytological examination, and were classified according to the Bethesda system. Patients from Undetermined Significance Or Follicular Lesion Of Undetermined Significance (AUS/FLUS), Follicular Neoplasm or Suspicious for a Follicular Neoplasm (FN/SFN), Suspicious for Malignant Cells (SMC), and Positive for Malignant Cells (PMC) groups were examined for the BRAF mutation and had a thyroid surgery. Demographical and histological features and stage of the disease were evaluated for PTC patients in accordance with the Bethesda category and its association with BRAF mutation.

resultsThree hundred eight of all patients underwent operation. One hundred forty-three (46.4%) of them were diagnosed with PTC. In 14 (9.8%) PTC cases, FNA biopsies were classified as AUS/FLUS, 23 (16.1%) as FN/SFN, 41 (28.7%) as SMC, and 65 (45.5%) as PMC. I-II stages of PTC were diagnosed for 88 (61.5%) patients and III-IVA for 55 (38.5%). Patients from the SMC and PMC groups had larger tumors, higher incidence of lymph node metastases, classical PTC type, B-type Raf (BRAF) positive, and III-IVA stage cancer, than patients from the AUS/FLUS and FN/SFN groups. When comparing 27 (18.9%) BRAF-negative patients from the AUS/FLUS and FN/SFN groups with 116 (81.1%) BRAF-negative patients from the SMC and PMC groups and all BRAF-positive patients, the prediction of more aggressive histological features and stage was slightly improved.

conclusionsHigher Bethesda categories are associated with higher stages of PTC. Association of the Bethesda category with BRAF mutation can slightly improve the value of stage prediction.

Indexed as

AdultAgedCarcinoma, PapillaryFemaleHumansMaleMiddle AgedMutationNeoplasm StagingPredictive Value of TestsProspective StudiesProto-Oncogene Proteins B-rafThyroid Cancer, PapillaryThyroidectomyThyroid NeoplasmsBRAF protein, humanProto-Oncogene Proteins B-rafBethesda systemBRAF mutationFine-needle aspirationPapillary thyroid cancerThyroid

Identifiers

PMID28160058

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.